{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:23:43Z","timestamp":1787955823814,"version":"build-2784847793"},"reference-count":85,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2020,1,27]]},"abstract":"<jats:sec><jats:title\/><jats:p>Targeted drug delivery systems gave newer dimensions for safer and more effective use of therapeutic drugs, thus helping in circumventing the issues of toxicity and unintended drug accumulation. These ongoing developments in delivery systems can, in turn, bring back drugs that suffered various limitations, Ellipticine (EPT) being a candidate. EPT derivatives witnessed entry into clinical settings but failed to survive in clinics citing various toxic side effects. A large body of preclinical data deliberates the potency of drug delivery systems in increasing the efficiency of EPT\/derivatives while decreasing their toxic side effects. Recent developments in drug delivery systems provide a platform to explore EPT and its derivatives as good clinical candidates in treating tumors. The present review deals with delivery mechanisms of EPT\/EPT derivatives as antitumor drugs, in vitro and in vivo, and evaluates the suitability of EPT-carriers in clinical settings.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1568009619666190927150131","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T13:59:30Z","timestamp":1569592770000},"page":"33-46","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Ellipticine, its Derivatives: Re-evaluation of Clinical Suitability with the Aid of Drug Delivery Systems"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6619-9014","authenticated-orcid":true,"given":"Vipin Mohan","family":"Dan","sequence":"first","affiliation":[{"name":"Microbiology Division, Jawaharlal Nehru Tropical Botanic Garden and Research Institute, Pacha-Palode 695562, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2698-7072","authenticated-orcid":true,"given":"Thania Sara","family":"Varghese","sequence":"additional","affiliation":[{"name":"Garden Management Division, Jawaharlal Nehru Tropical Botanic Garden and Research Institute, Pacha-Palode 695562, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8439-6724","authenticated-orcid":true,"given":"Gayathri","family":"Viswanathan","sequence":"additional","affiliation":[{"name":"Phytochemistry and Phytopharmacology Division, Jawaharlal Nehru Tropical Botanic Garden and Research Institute, Pacha-Palode 695562, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4337-9431","authenticated-orcid":true,"given":"Sabulal","family":"Baby","sequence":"additional","affiliation":[{"name":"Phytochemistry and Phytopharmacology Division, Jawaharlal Nehru Tropical Botanic Garden and Research Institute, Pacha-Palode 695562, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1021\/ja01517a031","volume":"81","author":"Goodwin S.","year":"1959","unstructured":"Goodwin S.; Smith A.F.; Horning E.C.; Alkaloids of Ochrosia elliptica Labill. J Am Chem Soc 1959,81,1903-1908","journal-title":"J Am Chem Soc"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1021\/ja01525a085","volume":"81","author":"Woodward R.B.","year":"1959","unstructured":"Woodward R.B.; Lacobucci G.A.; Hochstein I.A.; The synthesis of ellipticine. J Am Chem Soc 1959,81,4434-4435","journal-title":"J Am Chem Soc"},{"key":"ref=3","first-page":"523","volume":"25","author":"Potier P.","year":"1973","unstructured":"Potier P.; Janot M.M.; Methoxy 9 ellipticine alcaloide du bois jaune de la Reunion (Ochrosia borbonica Gmel.). Ann Pharm Fr 1973,25,523-524","journal-title":"Ann Pharm Fr"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/S0031-9422(82)85057-7","volume":"2","author":"Morafaux A.M.","year":"1982","unstructured":"Morafaux A.M.; Mulamba T.; Richard B.; Delaude C.; Massiot G.; Le Men Oliver L.; Alkaloids of Pterotaberna inconspicua. Phytochemistry 1982,2,1767-1769","journal-title":"Phytochemistry"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"8883","DOI":"10.1039\/c2ra20584j","volume":"2","author":"Miller C.M.","year":"2012","unstructured":"Miller C.M.; McCarthy F.O.; Isolation, biological activity and synthesis of the natural product ellipticine and related pyridocarbazoles. RSC Advances 2012,2,8883-8918","journal-title":"RSC Advances"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.apjtb.2017.10.016","volume":"7","author":"Iqbal J.","year":"2017","unstructured":"Iqbal J.; Abbasi B.A.; Mahmood T.; Kanwal S.; Ali B.; Shah S.A.; Khalil A.T.; Plant-derived anticancer agents: A green anticancer approach. Asian Pac J Trop Biomed 2017,7,1129-1150","journal-title":"Asian Pac J Trop Biomed"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1016\/S0040-4039(00)92862-4","volume":"21","author":"Michel S.","year":"1980","unstructured":"Michel S.; Tillequin F.; Koch M.; 17-Oxo ellipticine a new alkaloid of Strychnos dinklagei. Tetrahedron Lett 1980,21,4027-4030","journal-title":"Tetrahedron Lett"},{"key":"ref=8","first-page":"239","volume":"39","author":"Gribble G.W.","year":"1990","unstructured":"Gribble G.W.; Synthesis and antitumour activity of ellipticine alkaloids and related compounds. The Alkaloids. Chemistry and Pharmacology 1990,39,239-352","journal-title":"Chemistry and Pharmacology"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/BF00270201","volume":"3","author":"Kouadio K.","year":"1984","unstructured":"Kouadio K.; Rideau M.; Ganser C.; Ch\u00e9nieux J.C.; Viel C.; Biotransformation of ellipticine into 5-formyl ellipticine by Choisya ternata strains. Plant Cell Rep a1984,3(5),203-205","journal-title":"Plant Cell Rep"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1021\/np50035a022","volume":"47","author":"Kouadio K.","year":"1984","unstructured":"Kouadio K.; Chenieux J.C.; Rideau M.; Viel C.; Viel C.; Antitumor alkaloids in callus cultures of Ochrosia elliptica. J Nat Prod b1984,47(5),872-874","journal-title":"J Nat Prod"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1071\/CH9672715","volume":"20","author":"Dalton L.K.","year":"1967","unstructured":"Dalton L.K.; Demerac S.; Elmes B.L.; Loder J.W.; Swan J.M.; Teitei T.; Synthesis of the tumor-inhibitory alkaloids, ellipticine, 9-methoxyellipticine, and related pyrido[,3-b]carbazoles. Aust J Chem 1967,20,2715-2727","journal-title":"Aust J Chem"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1021\/jm00118a014","volume":"31","author":"Larue L.","year":"1988","unstructured":"Larue L.; Rivalle C.; Muzard G.; Paoletti C.; Bisagni E.; Paoletti J.; A new series of ellipticine derivatives (1-(alkylamino)-9-methoxyellipticine). Synthesis, DNA binding, and biological properties. J Med Chem 1988,31(10),1951-1956","journal-title":"J Med Chem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"7106","DOI":"10.1021\/jo070774z","volume":"72","author":"Liu C.Y.","year":"2007","unstructured":"Liu C.Y.; Knochel P.; Preparation of polyfunctional aryl azides from aryl triazenes. A new synthesis of ellipticine, 9-methoxyellipticine, isoellipticine, and 7-carbethoxyisoellipticine. J Org Chem 2007,72(19),7106-7115","journal-title":"J Org Chem"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.24820\/ark.5550190.p010.445","volume":"i","author":"Ibrahim-Ouali M.","year":"2018","unstructured":"Ibrahim-Ouali M.; Dummer F.; Recent syntheses of ellipticine and its derivatives. ARKIVOC 2018,i,216-243","journal-title":"ARKIVOC"},{"key":"ref=15","first-page":"195","volume":"5:2","author":"Hahn F.E.","year":"1979","unstructured":"Hahn F.E.; Hahn, F.E., Ed.; Ellipticine, In: Antibiotics: Mechanism of Action of Antieukaryotic and Antiviral Compounds 1979,5:2,195-213"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/0166-1280(92)85054-O","volume":"257","author":"Dantas S.O.","year":"1992","unstructured":"Dantas S.O.; Galvao D.S.; An investigation of the electronic structure of the antitumour drug ellipticine and its derivatives. Part II. Spectroscopic INDO\/CI study. J Mol Struct THEOCHEM 1992,257,437-449","journal-title":"J Mol Struct THEOCHEM"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"14998","DOI":"10.1074\/jbc.270.25.14998","volume":"270","author":"Froelich-Ammon S.J.","year":"1995","unstructured":"Froelich-Ammon S.J.; Patchan M.W.; Osheroff N.; Thompson R.B.; Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy. J Biol Chem 1995,270(25),14998-15004","journal-title":"J Biol Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1039\/C1NP00054C","volume":"29","author":"Hamilton P.L.","year":"2012","unstructured":"Hamilton P.L.; Arya D.P.; Natural product DNA major groove binders. Nat Prod Rep 2012,29(2),134-143","journal-title":"Nat Prod Rep"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2174\/1568011043482070","volume":"4","author":"Garbett N.C.","year":"2004","unstructured":"Garbett N.C.; Graves D.E.; Extending nature\u2019s leads: the anticancer agent ellipticine. Curr Med Chem Anticancer Agents 2004,4(2),149-172","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5507\/bp.2006.002","volume":"150","author":"Stiborova M.","year":"2006","unstructured":"Stiborova M.; Rupertova M.; Schmeiser H.H.; Frei E.; Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2006,150(1),13-23","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.bbapap.2010.05.016","volume":"1814","author":"Stiborov\u00e1 M.","year":"2011","unstructured":"Stiborov\u00e1 M.; Rupertov\u00e1 M.; Frei E.; Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency. Biochim Biophys Acta 2011,1814(1),175-185","journal-title":"Biochim Biophys Acta"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2478\/v10102-011-0017-7","volume":"4","author":"Stiborov\u00e1 M.","year":"2011","unstructured":"Stiborov\u00e1 M.; Poljakov\u00e1 J.; Mart\u00ednkov\u00e1 E.; Bo\u0159ek-Dohalsk\u00e1 L.; Eckschlager T.; Kizek R.; Frei E.; Ellipticine cytotoxicity to cancer cell lines - a comparative study. Interdiscip Toxicol b2011,4(2),98-105","journal-title":"Interdiscip Toxicol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.tox.2012.08.004","volume":"302","author":"Stiborov\u00e1 M.","year":"2012","unstructured":"Stiborov\u00e1 M.; Poljakov\u00e1 J.; Mart\u00ednkov\u00e1 E.; Ulrichov\u00e1 J.; Sim\u00e1nek V.; Dvo\u0159\u00e1k Z.; Frei E.; Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5. Toxicology 2012,302(2-3),233-241","journal-title":"Toxicology"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1074\/jbc.M112.411611","volume":"288","author":"Andrews W.J.","year":"2013","unstructured":"Andrews W.J.; Panova T.; Normand C.; Gadal O.; Tikhonova I.G.; Panov K.I.; Old drug, new target: ellipticines selectively inhibit RNA polymerase I transcription. J Biol Chem 2013,288(7),4567-4582","journal-title":"J Biol Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3390\/ijms16010284","volume":"16","author":"Stiborov\u00e1 M.","year":"2014","unstructured":"Stiborov\u00e1 M.; \u010cern\u00e1 V.; Moserov\u00e1 M.; Mr\u00edzov\u00e1 I.; Arlt V.M.; Frei E.; The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, Hepatic Cytochrome P450 Reductase Null (HRN\u2122) mice and pure enzymes. Int J Mol Sci 2014,16(1),284-306","journal-title":"Int J Mol Sci"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.1073\/pnas.71.12.5078","volume":"71","author":"Le Pecq J.B.","year":"1974","unstructured":"Le Pecq J.B.; Nguyen-Dat-Xuong; Gosse, C.; Paoletti, C. A new antitumoral agent: 9-hydroxyellipticine. Possibility of a rational design of anticancerous drugs in the series of DNA intercalating drugs. Proc Natl Acad Sci USA 1974,71(12),5078-5082","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=27","first-page":"77","volume":"5","author":"Schwaller M.A.","year":"1990","unstructured":"Schwaller M.A.; Aubard J.; Dodin G.; Kinetic and thermodynamic studies on drug-DNA interactions in the ellipticine series. Anticancer Drug Des 1990,5(1),77-87","journal-title":"Anticancer Drug Des"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0006-2952(01)00806-1","volume":"62","author":"Stiborov\u00e1 M.","year":"2001","unstructured":"Stiborov\u00e1 M.; Bieler C.A.; Wiessler M.; Frei E.; The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol 2001,62(12),1675-1684","journal-title":"Biochem Pharmacol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"11446","DOI":"10.1021\/jp062778y","volume":"110","author":"Fung S.Y.","year":"2006","unstructured":"Fung S.Y.; Duhamel J.; Chen P.; Solvent effect on the photophysical properties of the anticancer agent ellipticine. J Phys Chem A 2006,110(40),11446-11454","journal-title":"J Phys Chem A"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0003-9861(87)90463-2","volume":"259","author":"Auclair C.","year":"1987","unstructured":"Auclair C.; Multimodal action of antitumor agents on DNA: the ellipticine series. Arch Biochem Biophys 1987,259(1),1-14","journal-title":"Arch Biochem Biophys"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-3-642-81488-4_15","volume":"74","author":"Paoletti C.","year":"1980","unstructured":"Paoletti C.; Le Pecq J.B.; Dat-Xuong N.; Juret P.; Garnier H.; Amiel J.L.; Rouesse J.; Antitumor activity, pharmacology, and toxicity of ellipticines, ellipticinium, and 9-hydroxy derivatives: preliminary clinical trials of 2-methyl-9-hydroxy ellipticinium (NSC 264-137). Recent Results Cancer Res 1980,74,107-123","journal-title":"Recent Results Cancer Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/S0006-3495(93)81273-6","volume":"65","author":"Sureau F.","year":"1993","unstructured":"Sureau F.; Moreau F.; Millot J.M.; Manfait M.; Allard B.; Aubard J.; Schwaller M.A.; Microspectrofluorometry of the protonation state of ellipticine, an antitumor alkaloid, in single cells. Biophys J 1993,65(5),1767-1774","journal-title":"Biophys J"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/adfm.200800860","volume":"19","author":"Fung S.Y.","year":"2009","unstructured":"Fung S.Y.; Yang H.; Bhola P.T.; Sadatmousavi P.; Muzar E.; Liu M.; Chen P.; Self-assembling peptide as a potential carrier for hydrophobic anticancer drug ellipticine: Complexation, release and in vitro delivery. Adv Funct Mater 2009,19,74-83","journal-title":"Adv Funct Mater"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/jps.10533","volume":"93","author":"Liu J.","year":"2004","unstructured":"Liu J.; Xiao Y.; Allen C.; Polymer-drug compatibility: a guide to the development of delivery systems for the anticancer agent, ellipticine. J Pharm Sci 2004,93(1),132-143","journal-title":"J Pharm Sci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1021\/bc0001544","volume":"12","author":"Searle F.","year":"2001","unstructured":"Searle F.; Gac-Breton S.; Keane R.; Dimitrijevic S.; Brocchini S.; Sausville E.A.; Duncan R.N.; -(2-hydroxypropyl) methacrylamide copolymer-6-(3-aminopropyl)-ellipticine conjugates. Synthesis, in vitro, and preliminary in vivo evaluation. Bioconjug Chem 2001,12(5),711-718","journal-title":"Bioconjug Chem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0168-3659(01)00314-5","volume":"74","author":"Nishiyama N.","year":"2001","unstructured":"Nishiyama N.; Kataoka K.; Preparation and characterization of size-controlled polymeric micelle containing cis-dichlorodia-mmineplatinum(II) in the core. J Control Release 2001,74(1-3),83-94","journal-title":"J Control Release"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0169-409X(02)00047-9","volume":"54","author":"Kabanov A.V.","year":"2002","unstructured":"Kabanov A.V.; Batrakova E.V.; Alakhov V.Y.; Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 2002,54(5),759-779","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0927-7765(99)00058-2","volume":"16","author":"Allen C.","year":"1999","unstructured":"Allen C.; Maysinger D.; Eisenberg A.; Nanoengineering block copolymer aggregates for drug delivery. Colloids Surf B Biointerfaces 1999,16,3-27","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1023\/A:1011054930439","volume":"18","author":"Benahmed A.","year":"2001","unstructured":"Benahmed A.; Ranger M.; Leroux J.C.; Novel polymeric micelles based on the amphiphilic diblock copolymer poly(N-vinyl-2-pyrrolidone)-block-poly(D,L-lactide). Pharm Res 2001,18(3),323-328","journal-title":"Pharm Res"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1002\/marc.201200453","volume":"33","author":"Sedlacek O.","year":"2012","unstructured":"Sedlacek O.; Monnery B.D.; Filippov S.K.; Hoogenboom R.; Hruby M.; Poly(2-oxazoline)s--are they more advantageous for biomedical applications than other polymers? Macromol Rapid Commun 2012,33(19),1648-1662","journal-title":"Macromol Rapid Commun"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1021\/bc100070g","volume":"21","author":"Maeda H.","year":"2010","unstructured":"Maeda H.; Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 2010,21(5),797-802","journal-title":"Bioconjug Chem"},{"key":"ref=42","first-page":"753","volume":"35","author":"Studenovsk\u00fd M.","year":"2015","unstructured":"Studenovsk\u00fd M.; Sedl\u00e1\u010dek O.; Hrub\u00fd M.; P\u00e1nek J.; Ulbrich K.; Multi-responsive polymer micelles as ellipticine delivery carriers for cancer therapy. Anticancer Res 2015,35(2),753-757","journal-title":"Anticancer Res"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/mabi.201300333","volume":"14","author":"Wang H.","year":"2014","unstructured":"Wang H.; Yang L.; Rempel G.L.; Preparation of pH-responsive polymer core-shell nanospheres for delivery of hydrophobic antineoplastic drug ellipticine. Macromol Biosci 2014,14(2),166-172","journal-title":"Macromol Biosci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1126\/science.1226338","volume":"338","author":"Cheng Z.","year":"2012","unstructured":"Cheng Z.; Al Zaki A.; Hui J.Z.; Muzykantov V.R.; Tsourkas A.; Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 2012,338(6109),903-910","journal-title":"Science"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"22982","DOI":"10.3390\/s141222982","volume":"14","author":"Stiborova M.","year":"2014","unstructured":"Stiborova M.; Manhartova Z.; Hodek P.; Adam V.; Kizek R.; Frei E.; Formation of DNA adducts by ellipticine and its micellar form in rats - a comparative study. Sensors (Basel) 2014,14(12),22982-22997","journal-title":"Sensors (Basel)"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"15369","DOI":"10.1039\/c2cp41708a","volume":"14","author":"Thakur R.","year":"2012","unstructured":"Thakur R.; Das A.; Chakraborty A.; Photophysical and photodynamical study of ellipticine: an anticancer drug molecule in bile salt modulated in vitro created liposome. Phys Chem Chem Phys 2012,14(44),15369-15378","journal-title":"Phys Chem Chem Phys"},{"key":"ref=47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001956","volume":"3","author":"Fung S.Y.","year":"2008","unstructured":"Fung S.Y.; Yang H.; Chen P.; Sequence effect of self-assembling peptides on the complexation and in vitro delivery of the hydrophobic anticancer drug ellipticine. PLoS One 2008,3(4)","journal-title":"PLoS One"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1073\/pnas.90.8.3334","volume":"90","author":"Zhang S.","year":"1993","unstructured":"Zhang S.; Holmes T.; Lockshin C.; Rich A.; Spontaneous assembly of a self-complementary oligopeptide to form a stable macroscopic membrane. Proc Natl Acad Sci USA 1993,90(8),3334-3338","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0006-3495(03)74498-1","volume":"85","author":"Fung S.Y.","year":"2003","unstructured":"Fung S.Y.; Keyes C.; Duhamel J.; Chen P.; Concentration effect on the aggregation of a self-assembling oligopeptide. Biophys J 2003,85(1),537-548","journal-title":"Biophys J"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.colsurfb.2006.12.002","volume":"55","author":"Fung S.Y.","year":"2007","unstructured":"Fung S.Y.; Yang H.; Chen P.; Formation of colloidal suspension of hydrophobic compounds with an amphiphilic self-assembling peptide. Colloids Surf B Biointerfaces 2007,55(2),200-211","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"7522","DOI":"10.1021\/ja0381297","volume":"126","author":"Keyes-Baig C.","year":"2004","unstructured":"Keyes-Baig C.; Duhamel J.; Fung S.Y.; Bezaire J.; Chen P.; Self-assembling peptide as a potential carrier of hydrophobic compounds. J Am Chem Soc 2004,126(24),7522-7532","journal-title":"J Am Chem Soc"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/bip.360340508","volume":"34","author":"Zhang S.","year":"1994","unstructured":"Zhang S.; Lockshin C.; Cook R.; Rich A.; Unusually stable beta-sheet formation in an ionic self-complementary oligopeptide. Biopolymers 1994,34(5),663-672","journal-title":"Biopolymers"},{"key":"ref=53","first-page":"3221","volume":"7","author":"Wu Y.","year":"2012","unstructured":"Wu Y.; Sadatmousavi P.; Wang R.; Lu S.; Yuan Y.F.; Chen P.; Self-assembling peptide-based nanoparticles enhance anticancer effect of ellipticine in vitro and in vivo. Int J Nanomedicine 2012,7,3221-3233","journal-title":"Int J Nanomedicine"},{"key":"ref=54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043684","volume":"7","author":"Ma W.","year":"2012","unstructured":"Ma W.; Lu S.; Pan P.; Sadatmousavi P.; Yuan Y.; Chen P.; Pharmacokinetics of peptide mediated delivery of anticancer drug ellipticine. PLoS One 2012,7(8)","journal-title":"PLoS One"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/nbt1267","volume":"24","author":"Hancock R.E.","year":"2006","unstructured":"Hancock R.E.; Sahl H.G.; Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006,24(12),1551-1557","journal-title":"Nat Biotechnol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.bbamem.2007.11.008","volume":"1778","author":"Hoskin D.W.","year":"2008","unstructured":"Hoskin D.W.; Ramamoorthy A.; Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta 2008,1778(2),357-375","journal-title":"Biochim Biophys Acta"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1039\/C6TB00529B","volume":"4","author":"Lu S.","year":"2016","unstructured":"Lu S.; Ding Y.; Wu Y.; Wang R.; Pan R.; Wan Z.; Xu W.; Zhang L.; Yuan Y-f.; Chen P.; An amphipathic lytic peptide for enhanced and selective delivery of ellipticine. J Mater Chem B Mater Biol Med 2016,4,4348-4355","journal-title":"J Mater Chem B Mater Biol Med"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.apsb.2018.01.007","volume":"8","author":"Zhou Y.","year":"2018","unstructured":"Zhou Y.; Quan G.; Wu Q.; Zhang X.; Niu B.; Wu B.; Huang Y.; Pan X.; Wu C.; Mesoporous silica nanoparticles for drug and gene delivery. Acta Pharm Sin B 2018,8(2),165-177","journal-title":"Acta Pharm Sin B"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1039\/C6BM00039H","volume":"4","author":"Baeza A.","year":"2016","unstructured":"Baeza A.; Manzano M.; Colilla M.; Vallet-Reg\u00ed M.; Recent advances in mesoporous silica nanoparticles for antitumor therapy: our contribution. Biomater Sci 2016,4(5),803-813","journal-title":"Biomater Sci"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.3390\/ma5122874","volume":"5","year":"2012","unstructured":"Z. A review: Fundamental aspects of silicate mesoporous materials. Materials (Basel) ALOthman2012,5,2874-2902","journal-title":"Materials (Basel)"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"18436","DOI":"10.1039\/C6NR06285G","volume":"8","author":"Koninti R.K.","year":"2016","unstructured":"Koninti R.K.; Palvai S.; Satpathi S.; Basu S.; Hazra P.; Loading of an anti-cancer drug into mesoporous silica nano-channels and its subsequent release to DNA. Nanoscale 2016,8(43),18436-18445","journal-title":"Nanoscale"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/adfm.200601191","volume":"17","author":"Slowing I.I.","year":"2007","unstructured":"Slowing I.I.; Trewyn B.G.; Giri S.; Lin V.S-Y.; Mesoporous silica nanoparticles for drug delivery and biosensing applications. Adv Funct Mater 2007,17,1225-1236","journal-title":"Adv Funct Mater"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1002\/smll.200901789","volume":"6","author":"Vivero-Escoto J.L.","year":"2010","unstructured":"Vivero-Escoto J.L.; Slowing I.I.; Trewyn B.G.; Lin V.S.; Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small 2010,6(18),1952-1967","journal-title":"Small"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"98080","DOI":"10.1039\/C5RA19839A","volume":"5","author":"Gavvala K.","year":"2015","unstructured":"Gavvala K.; Satpathi S.; Hazra P.; pH responsive translocation of an anticancer drug between cyclodextrin and DNA. RSC Advances 2015,5,98080-98086","journal-title":"RSC Advances"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1039\/c3cp54422b","volume":"16","author":"Sengupta A.","year":"2014","unstructured":"Sengupta A.; Koninti R.K.; Gavvala K.; Ballav N.; Hazra P.; An anticancer drug to probe non-specific protein-DNA interactions. Phys Chem Chem Phys 2014,16(9),3914-3917","journal-title":"Phys Chem Chem Phys"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"8778","DOI":"10.1021\/ja200328s","volume":"133","author":"Muhammad F.","year":"2011","unstructured":"Muhammad F.; Guo M.; Qi W.; Sun F.; Wang A.; Guo Y.; Zhu G.; pH-Triggered controlled drug release from mesoporous silica nanoparticles via intracelluar dissolution of ZnO nanolids. J Am Chem Soc 2011,133(23),8778-8781","journal-title":"J Am Chem Soc"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1021\/ja028650l","volume":"125","author":"Lai C.Y.","year":"2003","unstructured":"Lai C.Y.; Trewyn B.G.; Jeftinija D.M.; Jeftinija K.; Xu S.; Jeftinija S.; Lin V.S.; A mesoporous silica nanosphere-based carrier system with chemically removable CdS nanoparticle caps for stimuli-responsive controlled release of neurotransmitters and drug molecules. J Am Chem Soc 2003,125(15),4451-4459","journal-title":"J Am Chem Soc"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.1016\/S0021-9258(19)50095-3","volume":"267","author":"Wilson K.P.","year":"1992","unstructured":"Wilson K.P.; Malcolm B.A.; Matthews B.W.; Structural and thermodynamic analysis of compensating mutations within the core of chicken egg white lysozyme. J Biol Chem 1992,267(15),10842-10849","journal-title":"J Biol Chem"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"7340","DOI":"10.1021\/jp0139484","volume":"106","author":"Deere J.","year":"2002","unstructured":"Deere J.; Magner E.; Wall J.G.; Hodnett B.K.; Mechanistic and structural features of protein adsorption onto mesoporous silicate. J Phys Chem B 2002,106,7340-7347","journal-title":"J Phys Chem B"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","volume":"93","author":"P\u00e9rez-Herrero E.","year":"2015","unstructured":"P\u00e9rez-Herrero E.; Fern\u00e1ndez-Medarde A.; Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 2015,93,52-79","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.coph.2006.04.006","volume":"6","author":"Marr A.K.","year":"2006","unstructured":"Marr A.K.; Gooderham W.J.; Hancock R.E.; Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol 2006,6(5),468-472","journal-title":"Curr Opin Pharmacol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.nano.2014.09.014","volume":"11","author":"Wang Y.","year":"2015","unstructured":"Wang Y.; Zhao Q.; Han N.; Bai L.; Li J.; Liu J.; Che E.; Hu L.; Zhang Q.; Jiang T.; Wang S.; Mesoporous silica nanoparticles in drug delivery and biomedical applications. Nanomedicine (Lond) 2015,11(2),313-327","journal-title":"Nanomedicine (Lond)"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1071\/CH9672715","volume":"20","author":"Dalton L.K.","year":"1967","unstructured":"Dalton L.K.; Demerac S.; Elmes B.C.; Loder J.W.; Swan J.M.; Teitei T.; Synthesis of the tumour-inhibitory alkaloids, ellipticine, 9-methoxyellipticine, and related pyrido[,3-b]carbazoles. Aust J Chem 1967,20,2715-2727","journal-title":"Aust J Chem"},{"key":"ref=74","first-page":"541","volume":"15","author":"Math\u00e9 G.","year":"1970","unstructured":"Math\u00e9 G.; Hayat M.; De Vassal F.; Schwarzenberg L.; Schneider M.; Schlumberger J.R.; Jasmin C.; Rosenfeld C.; Methoxy-9-ellipticine lactate. 3. Clinical screening: its action in acute myeloblastic leukaemia. Rev Eur Etud Clin Biol 1970,15(5),541-545","journal-title":"Rev Eur Etud Clin Biol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1136\/pgmj.51.592.103","volume":"51","author":"Ansari B.M.","year":"1975","unstructured":"Ansari B.M.; Thompson E.N.; Methoxy-9-ellipticine lactate in refractory acute myeloid leukaemia. Postgrad Med J 1975,51(592),103-105","journal-title":"Postgrad Med J"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/B978-0-444-62649-3.00007-7","author":"Avenda\u00f1o C.","year":"2015","unstructured":"Avenda\u00f1o C.; Menendez J.C.; Other anticancer drugs targeting DNA and DNA-associated enzymes Med Chem Anti-cancer Drugs 2015,273-323","journal-title":"Other anticancer drugs targeting DNA and DNA-associated enzymes Med Chem Anti-cancer Drugs"},{"key":"ref=77","first-page":"1495","volume":"8","author":"Juret P.","year":"1979","unstructured":"Juret P.; Tanguy A.; Girard A.; Le Talaer J.Y.; Abbatucci J.S.; Dat-Yuong, Le Pecq, J.B.; Paoletti, C. Hydroxy 9-methyl 2-ellipticinium acetate (NSC 264-137). Toxicologic study and therapeutic effect in 100 cancers (author\u2019s transl). Nouv Presse Med 1979,8,1495-1498","journal-title":"Nouv Presse Med"},{"key":"ref=78","first-page":"1909","volume":"66","author":"Juret P.","year":"1982","unstructured":"Juret P.; Heron J.F.; Couette J.E.; Delozier T.; Le Talaer J.Y.; Hydroxy-9-methyl-2-ellipticinium for osseous metastases from breast cancer: a 5-year experience. Cancer Treat Rep 1982,66(11),1909-1916","journal-title":"Cancer Treat Rep"},{"key":"ref=79","first-page":"707","volume":"69","author":"Rou\u00ebsse J.G.","year":"1985","unstructured":"Rou\u00ebsse J.G.; Le Chevalier T.; Caille P.; Mondesir J.M.; Sancho-Garnier H.; May-Levin F.; Spielmann M.; De Jager R.; Amiel J.L.; Phase II study of elliptinium in advanced breast cancer. Cancer Treat Rep 1985,69(6),707-708","journal-title":"Cancer Treat Rep"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF00170864","volume":"7","author":"Treat J.","year":"1989","unstructured":"Treat J.; Greenspan A.; Rahman A.; McCabe M.S.; Byrne P.J.; Elliptinium: phase II study in advanced measurable breast cancer. Invest New Drugs 1989,7(2-3),231-234","journal-title":"Invest New Drugs"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1200\/JCO.1985.3.5.735","volume":"3","author":"Mondesir J.M.","year":"1985","unstructured":"Mondesir J.M.; Bidart J.M.; Goodman A.; Alberici G.F.; Caille P.; Troalen F.; Rouesse J.; Bohuon C.; Gralla R.J.; Einzig A.I.; Drug-induced antibodies during 2-N-methyl-9-hydroxyellipticinium acetate (NSC-264137) treatment: schedule dependency and relationship to hemolysis. J Clin Oncol 1985,3(5),735-740","journal-title":"J Clin Oncol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000226797","volume":"47","author":"Buzdar A.U.","year":"1990","unstructured":"Buzdar A.U.; Hortobagyi G.N.; Esparza L.T.; Holmes F.A.; Ro J.S.; Fraschini G.; Lichtiger B.; Elliptinium acetate in metastatic breast cancer--a phase II study. Oncology 1990,47(2),101-104","journal-title":"Oncology"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40169-017-0175-0","volume":"6","author":"Tran S.","year":"2017","unstructured":"Tran S.; DeGiovanni P.J.; Piel B.; Rai P.; Cancer nanomedicine: a review of recent success in drug delivery. Clin Transl Med 2017,6(1),44-53","journal-title":"Clin Transl Med"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S1470-2045(18)30332-2","volume":"19","author":"Lyon P.C.","year":"2018","unstructured":"Lyon P.C.; Gray M.D.; Mannaris C.; Folkes L.K.; Stratford M.; Campo L.; Chung D.Y.F.; Scott S.; Anderson M.; Goldin R.; Carlisle R.; Wu F.; Middleton M.R.; Gleeson F.V.; Coussios C.C.; Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial. Lancet Oncol 2018,19(8),1027-1039","journal-title":"Lancet Oncol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40349-017-0104-0","volume":"5","author":"Lyon P.C.","year":"2017","unstructured":"Lyon P.C.; Griffiths L.F.; Lee J.; Chung D.; Carlisle R.; Wu F.; Middleton M.R.; Gleeson F.V.; Coussios C.C.; Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox) using focused ultrasound in patients with liver tumours. J Ther Ultrasound 2017,5,28-32","journal-title":"J Ther Ultrasound"}],"container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/175187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T15:57:35Z","timestamp":1611417455000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/175187\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,27]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,27]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568009619666190927150131","relation":{},"ISSN":["1568-0096"],"issn-type":[{"value":"1568-0096","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,27]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-04-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}